logo
  

Quintiles Q3 Profit Advances; Raises Annual Earnings Outlook - Quick Facts

Quintiles Transnational Holdings Inc. (Q) Thursday reported a rise in earnings as well as revenues for the third quarter. The company lifted its annual earnings outlook, but lowered its expectations for services revenue.

For the three months to September, net earnings increased to $92.65 million or $0.71 per share, from $66.77 million or $0.50 per share a year earlier.

Excluding certain items, net earnings were $84.98 million or $0.65 per share.

On average, eighteen analysts polled by Thomson-Reuters estimated earnings to be $0.64. Analysts' estimates typically exclude one-time items.

Revenues rose to $1.4 billion, from $1.19 billion last year. Analysts expected revenues of $1.05 billion.

Looking ahead, Quintiles raised its adjusted annual earnings outlook to $2.61 - $2.68 per share, from the prior guidance of $2.57 to $2.67. Quintiles also raised its annual net earnings guidance to $2.61 - $2.68 per share, from $2.49 - $2.61 per share previously projected.

The company, however, lowered its annual services revenue outlook to $4.16 billion and $4.19 billion, from the $4.20 billion and $4.24 billion previously projected.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT